Study of Navtemadlin Plus Pembrolizumab as Maintenance Therapy in Locally Advanced and Metastatic Non-Small Cell Lung Cancer

NCT05705466 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

WITHDRAWN

Status

INDUSTRY

Sponsor class

Stopped Sponsor Decision

Conditions

Non Small Cell Lung Cancer

Interventions

DRUG: Navtemadlin
DRUG: Navtemadlin Placebo
DRUG: Pembrolizumab

Sponsor

Kartos Therapeutics, Inc.